PEMPFIX
LIVE

Serial Number

79212465

Owner

Novalis Investments S.L.

Filing Date

Jun 2, 2016

Add to watchlist:

No watchlists yet
View on USPTO

PEMPFIX Trademark

Serial Number: 79212465 • Registration: 5440650

PEMPFIX is a trademark filed by Novalis Investments S.L. on June 2, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Novalis Investments S.L.

Urb CASHBAH del Saler 2, 56

Entity Type: 99

Immungenetics AG (3 trademarks)

Eifflerstr. 43

Entity Type: 25

Trademark Details

Filing Date

June 2, 2016

Registration Date

April 10, 2018

Published for Opposition

January 23, 2018

Cancellation Date

October 25, 2024

Goods & Services

Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseases, cancer, infectious diseases, fungal diseases, diseases caused by parasites, eye diseases, diseases of the central and peripheral nervous systems, cardiovascular diseases, diseases affecting the immune system, genetic diseases, single gene disorders, mouth, teeth, skin, hair and ear diseases, bone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseases, in particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseases, in particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoide, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systems, in particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseases, in particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseases, in particular for the treatment of psoriasis, lupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucosal pemphigoid, lichen planus pemphigoid, anti-laminin gamal/p200 pemphigoid, epidermolysis bullosa acquisita, dermatitis herpetiformis, in particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous system, in particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticals, in particular creams, dispersions, lotions, ointments, fluids, solutions, sprays, plasters, lacquer and filmforming solutions, for the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseases, inflammatory diseases, skin, hair and ear diseases; oral administration pharmaceuticals preparations, in particular pills, tablets, lozenges, capsules, liquids, solutions, drops, for the prevention and treatment of central nervous system diseases

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Dec 25, 2025 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 4, 2025 INTS
INVALIDATION PROCESSED
Dec 4, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 25, 2025 INTR
CANCELLED SECTION 71
Oct 25, 2024 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 10, 2023 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2021 NREP
CHANGE OF OWNER RECEIVED FROM IB
Apr 30, 2020 CHLD
NEW REPRESENTATIVE AT IB RECEIVED
Jul 26, 2019 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 24, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 30, 2018 FICS
FINAL DISPOSITION PROCESSED
Jul 30, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 10, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 10, 2018 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 21, 2018 TCCA
PUBLISHED FOR OPPOSITION
Jan 23, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Jan 19, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 3, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 3, 2018 OP2R
NOTICE OF PUBLICATION
Jan 3, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 19, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 27, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 27, 2017 CRFA
ASSIGNED TO LIE
Nov 19, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2017 TROA
REFUSAL PROCESSED BY IB
Aug 18, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 1, 2017 RFCS
REFUSAL PROCESSED BY MPU
Aug 1, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jul 31, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Jul 25, 2017 MAFR
ASSIGNED TO EXAMINER
Jul 19, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 19, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 13, 2017 REPR